Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 50,452 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: control Clear all
Recruiting Not applicable Interventional

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

NCT06785324
View directory record Official record
Conditions
Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL
Interventions
Nutrition Intervention, Exercise intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 19, 2026, 1:58 AM EDT
Not listed Not applicable Interventional

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
RGMA001, Sugar Pill
Dietary Supplement
Lead sponsor
Biovil Research Group, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 3 Interventional

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

NCT03720223
View directory record Official record
Conditions
Urethral Stricture
Interventions
Liposomal Bupivacaine
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 19, 2026, 1:58 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 19, 2026, 1:58 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Multilevel Intervention to Prevent Noise Exposure in Farmworkers

NCT07554378
View directory record Official record
Conditions
Noise Exposure, Hearing Loss, Noise-Induced, Occupational Exposure
Interventions
Multilevel Hearing Protection Training
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Dementia and Diabetes Prevention Program

NCT04141878
View directory record Official record
Conditions
Diabetes, Dementia
Interventions
Aerobic Exercise, Diet Skills
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
60 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 ( naftin 2 % gel ), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Feasibility and Acceptability of a Pediatric Referral to Summer Day Camps to Treat Obesity in Children From Low-Income Households

NCT07464015
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Summer Day Camp
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
5 Years to 11 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement

NCT02875015
View directory record Official record
Conditions
Postoperative Pain
Interventions
Liposomal Bupivacaine, Bupivacaine Hydrochloride and Lidocaine, Suburethral Sling
Drug · Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
19 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Morristown, New Jersey • Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

IN Sub-Dissociative Ketamine vs IN Fentanyl

NCT02521415
View directory record Official record
Conditions
Bone Fracture
Interventions
ketamine, fentanyl, ibuprofen or acetaminophen
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
4 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

NCT03037515
View directory record Official record
Conditions
Blood Loss, Surgical, Blood Loss Anemia
Interventions
Tranexamic Acid
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 1:58 AM EDT
Withdrawn Not applicable Interventional

Acupuncture for Mucositis Pain in Cancer Care

NCT00549835
View directory record Official record
Conditions
Mucositis, Pain, Leukemia
Interventions
Real Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional Results available

Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding

NCT02640235
View directory record Official record
Conditions
Bleeding Active
Interventions
CELSTAT, Surgicel Original
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

NCT02925117
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Tampa, Florida • Sandy Springs, Georgia • Rockville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism and Bariatric Surgery Study

NCT03371368
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Very Low Calorie Diet (VLCD)
Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Apoyo Con Carino: Patient Navigation for Palliative Care for Non-Cancer Illness

NCT03181750
View directory record Official record
Conditions
Palliative Care
Interventions
Patient Navigator Intervention Group
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

NCT01186991
View directory record Official record
Conditions
Breast Cancer
Interventions
Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
23
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Sleep To Reduce Incident Depression Effectively

NCT03322774
View directory record Official record
Conditions
Insomnia, Primary, Major Depressive Disorder, Rumination
Interventions
digital Cognitive Behavioral Therapy for Insomnia, face-to-face Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education Control
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Trial of a Mammography Decision Aid for Women Aged 75 and Older

NCT02198690
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
Mammography decision aid, Home safety pamphlet
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
75 Years to 89 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention

NCT03855410
View directory record Official record
Conditions
Tobacco Use, Drug Use, Adolescent Behavior, Alcohol Use, Sexual Risk Behavior
Interventions
S4E, Attention-Matched Control Group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 1:58 AM EDT